Provention Bio Inc. (PRVB) and Array BioPharma Inc. (NASDAQ:ARRY) Comparing side by side

We are comparing Provention Bio Inc. (NASDAQ:PRVB) and Array BioPharma Inc. (NASDAQ:ARRY) on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Provention Bio Inc. N/A 0.00 24.88M -0.74 0.00
Array BioPharma Inc. 180.09M 28.64 111.47M -0.53 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Provention Bio Inc. and Array BioPharma Inc.

Profitability

Table 2 represents Provention Bio Inc. (NASDAQ:PRVB) and Array BioPharma Inc. (NASDAQ:ARRY)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Provention Bio Inc. 0.00% 0% 0%
Array BioPharma Inc. -61.90% -45.1% -22.4%

Liquidity

Provention Bio Inc.’s Current Ratio is 53.7 while its Quick Ratio is 53.7. On the competitive side is, Array BioPharma Inc. which has a 6.3 Current Ratio and a 6.3 Quick Ratio. Provention Bio Inc. is better positioned to pay off short and long-term obligations compared to Array BioPharma Inc.

Analyst Ratings

Recommendations and Ratings for Provention Bio Inc. and Array BioPharma Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Provention Bio Inc. 0 0 0 0.00
Array BioPharma Inc. 0 1 4 2.80

On the other hand, Array BioPharma Inc.’s potential upside is 7.87% and its consensus target price is $25.5.

Insider & Institutional Ownership

Provention Bio Inc. and Array BioPharma Inc. has shares owned by institutional investors as follows: 6.1% and 0%. Insiders owned roughly 13.9% of Provention Bio Inc.’s shares. Competitively, 0.4% are Array BioPharma Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Provention Bio Inc. -2.72% -1.96% 0.81% -34.9% 0% 41.24%
Array BioPharma Inc. 0.72% 26.73% 45.15% 53.84% 33.98% 66.04%

For the past year Provention Bio Inc. has weaker performance than Array BioPharma Inc.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.